Within this dynamic landscape, the integration of CRISPR-Cas13a into antimicrobial strategies stands out as a promising approach to tackle antibiotic-resistant bacterial infections 5. The clinical applicability of this CRISPR technology is attributed largely to the intrinsic collateral cleavage activity of certain subtypes of the CRISPR system, including, but not limited to, CRISPR-Cas13. When CRISPR-Cas13, primed with short CRISPR RNA (crRNA), recognizes and binds to its target RNA, a preceding specific RNA cleavage triggers conformational changes in the CRISPR-Cas13 protein to a non-specific RNase, resulting in indiscriminate cleavage of host RNAs, namely collateral cleavage 6. This unique feature of CRISPR-Cas13 has been adopted by our laboratory for the development of an alternative antimicrobial agent capable of accomplishing sequence-specific killing of target antibiotic-resistant bacteria 5, 7.